These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32773667)

  • 1. Evidence of Dose Variability and Dosing Below the FDA and EMA Recommendations for Intravenous Colistin (Polymyxin E) Use in Children and Neonates.
    Chin MKY; Hsia Y; Goossens H; Versporten A; Bielicki J; Sharland M; Donà D
    Pediatr Infect Dis J; 2020 Nov; 39(11):1032-1034. PubMed ID: 32773667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous colistin administration in neonates.
    Jajoo M; Kumar V; Jain M; Kumari S; Manchanda V
    Pediatr Infect Dis J; 2011 Mar; 30(3):218-21. PubMed ID: 21245777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colistin administration to pediatric and neonatal patients.
    Iosifidis E; Antachopoulos C; Ioannidou M; Mitroudi M; Sdougka M; Drossou-Agakidou V; Tsivitanidou M; Roilides E
    Eur J Pediatr; 2010 Jul; 169(7):867-74. PubMed ID: 20119725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria.
    Pintado V; San Miguel LG; Grill F; Mejía B; Cobo J; Fortún J; Martín-Dávila P; Moreno S
    J Infect; 2008 Mar; 56(3):185-90. PubMed ID: 18280570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous colistin use for infections due to MDR Gram-negative bacilli in critically ill paediatric patients: a systematic review and meta-analysis.
    Karageorgos SA; Bassiri H; Siakallis G; Miligkos M; Tsioutis C
    J Antimicrob Chemother; 2019 Sep; 74(9):2497-2506. PubMed ID: 31049586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational use of intravenous polymyxin B and colistin: A review.
    Zakuan ZD; Suresh K
    Med J Malaysia; 2018 Oct; 73(5):351-359. PubMed ID: 30350826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug-resistant Gram-negative infections: the use of colistin.
    Michalopoulos AS; Karatza DC
    Expert Rev Anti Infect Ther; 2010 Sep; 8(9):1009-17. PubMed ID: 20818945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis.
    Falagas ME; Sideri G; Vouloumanou EK; Papadatos JH; Kafetzis DA
    Pediatr Infect Dis J; 2009 Feb; 28(2):123-7. PubMed ID: 19116601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous colistin for the treatment of multi-drug resistant, gram-negative infection in the pediatric burn population.
    Goverman J; Weber JM; Keaney TJ; Sheridan RL
    J Burn Care Res; 2007; 28(3):421-6. PubMed ID: 17438490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics of Intravenous Colistin in Pediatric Patients: Implications for the Selection of Dosage Regimens.
    Ooi MH; Ngu SJ; Chor YK; Li J; Landersdorfer CB; Nation RL
    Clin Infect Dis; 2019 Nov; 69(11):1962-1968. PubMed ID: 30722017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of intravenous colistin in children.
    Kumar PP; Giri SR; Shaikh FA; Panigrahy N; Chirla D
    Indian Pediatr; 2015 Feb; 52(2):129-30. PubMed ID: 25691180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Use of Colistin for the Treatment of Multidrug-resistant Gram-negative Infections in Neonates and Infants: A Review of the Literature.
    Nakwan N; Chokephaibulkit K; Imberti R
    Pediatr Infect Dis J; 2019 Nov; 38(11):1107-1112. PubMed ID: 31469781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colistin, an Old Drug in a New Territory, Solid Organ Transplantation.
    Florescu DF; Mindru C; Keck MA; Qiu F; Kalil AC
    Transplant Proc; 2016; 48(1):152-7. PubMed ID: 26915861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colistin Area Under the Time-Concentration in Children Treated With Intravenous Loading Dose and Maintenance Therapy.
    Mesini A; Loy A; Gattorno M; Moscatelli A; Bandettini R; Faraci M; Cangemi G; Castagnola E
    Clin Infect Dis; 2018 Feb; 66(5):808-809. PubMed ID: 29020309
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial pneumonia: a case series.
    Falagas ME; Siempos II; Rafailidis PI; Korbila IP; Ioannidou E; Michalopoulos A
    Respir Med; 2009 May; 103(5):707-13. PubMed ID: 19118994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria.
    Falagas ME; Kasiakou SK; Kofteridis DP; Roditakis G; Samonis G
    Eur J Clin Microbiol Infect Dis; 2006 Sep; 25(9):596-9. PubMed ID: 16955249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous combined with aerosolised polymyxin versus intravenous polymyxin alone in the treatment of pneumonia caused by multidrug-resistant pathogens: a systematic review and meta-analysis.
    Liu D; Zhang J; Liu HX; Zhu YG; Qu JM
    Int J Antimicrob Agents; 2015 Dec; 46(6):603-9. PubMed ID: 26607337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
    Kasiakou SK; Michalopoulos A; Soteriades ES; Samonis G; Sermaides GJ; Falagas ME
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3136-46. PubMed ID: 16048915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections.
    Huang J; Tang YQ; Sun JY
    Scand J Infect Dis; 2010 Apr; 42(4):260-5. PubMed ID: 20085424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).
    Tsuji BT; Pogue JM; Zavascki AP; Paul M; Daikos GL; Forrest A; Giacobbe DR; Viscoli C; Giamarellou H; Karaiskos I; Kaye D; Mouton JW; Tam VH; Thamlikitkul V; Wunderink RG; Li J; Nation RL; Kaye KS
    Pharmacotherapy; 2019 Jan; 39(1):10-39. PubMed ID: 30710469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.